Global Portfolio Leader - Electronics

Schrödinger 2026-3 release advances composite matrix design tools. The update adds coarse-grained backmapping for resin structure modeling and an agentic AI co-scientist, Bunsen, now in beta. Senior Managing Editor, CompositesWorld and Products Finishing Source | Schrödinger Schrödinger (New York, N.Y., U.S.) has released the 2026-3 version of its Materials Science Suite, adding capabilities the company says advance the digital design of composite matrix formulations alongside a new agentic AI tool, machine learning model refinements and expanded structure prediction tools. The release is available for download to Schrödinger users. A central addition is coarse-grained backmapping, which maps coarse-grained structures to all-atom molecular models. According to Schrödinger, this enables development of structural models for complex resin mixtures, supporting property assessment across length scales relevant to composite matrix formulation. Learn to cut the cost and time of tooling. CW's editors are tracking the latest trends and developments in tooling, from the basics to new developments. This collection, presented by Composites One, features recent CW stories that detail a range of tooling technologies, processes and materials. Download Collection The release also updates MS Reactivity workflows, aimed at exploring degradation behavior in polymer systems. The Nanoreactor tool within that workflow now includes a simplified interface with dedicated tabs for workflow and sampling settings, along with a scaled setup for biasing potential, changes that provide more robust tools for assessing thermal and other degradation risks. Along with the release, Schrödinger also officially introduced Bunsen, a chemistry-native agentic co-scientist now available to early access customers. The tool is designed to execute complex workflows, submit and monitor jobs, and self-correct in real time. Additional enhancements in the release include a custom extension of Schrödinger's foundational machine learning force field, which allows users to refine MPNICE force field parameters using custom structure-energy data for specific chemical spaces, and enhanced featurization for solid-state machine learning, which builds machine learning models based on MPNICE embeddings. The release additionally includes extended crystal structure prediction capability, capable of predicting crystal structures for salts, hydrates, solvates and cocrystals. * Testing to support composite bolted joint analysis An overview of ASTM Standard Guide D8509, and its coupon-level mechanical testing of design properties for analyzing composite bolted joints. * Cutting 100 pounds, certification time for the X-59 nose cone Swift Engineering used HyperX software to remove 100 pounds from 38-foot graphite/epoxy cored nose cone for X-59 supersonic aircraft. * Troubleshooting thermoplastic composite stamp forming Understand the basic science of TPC stamp forming, a manufacturing process steadily gaining momentum in aerospace and mobility applications thanks to its rapid forming, short cycle times and automated methods.

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.

Schrödinger announces strategic collaboration and software agreement with Bristol Myers Squibb to deploy AI co-scientist Bunsen. Aug. 5, 2026 Press Contacts Jaren Madden Matthew Luchini Theresa Masnik NEW YORK - Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. Building on a long-standing partnership with BMS where they routinely utilize Schrödinger's industry-leading computational platform, the new agreement significantly expands the application of Schrödinger's platform, empowering BMS scientists to explore more scientific possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions. Under the agreement, Schrödinger will collaborate with BMS scientists on developing novel functionality within Bunsen in conjunction with its computational technologies designed to enable large-scale chemical exploration as well as with RetroSynth, its AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimized to execute Schrödinger's validated, physics-based computational platform by planning and running complex molecular discovery workflows and interpreting the results. "BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. We are thrilled they are deploying Bunsen at a large scale," said Robert Abel, Chief Scientific Officer, Platform, of Schrödinger. "Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach." "Over the past several years, AI has become a key enabler for our scientists, allowing them to scale their creativity and scientific expertise across our research organization," said Stephen Johnson, Vice President, Computational Sciences, Bristol Myers Squibb. "Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients." About Bunsen Bunsen is Schrödinger's agentic AI co-scientist, built specifically for molecular discovery. Optimized to execute Schrödinger's validated computational methods, Bunsen helps researchers understand scientific objectives, plan computational strategies, execute sophisticated discovery workflows, and interpret results. By combining AI with physics-based simulation, Bunsen makes advanced computational methods more accessible and enables research teams to evaluate more hypotheses, systematically explore broader chemical space, and make higher-confidence decisions prior to experimental testing. To learn more about Bunsen and sign up for priority access, visit the company's Bunsen webpage. About Retrosynth RetroSynth is Schrödinger's AI-driven synthesis planning platform designed to rapidly evaluate synthetic feasibility and optimize route selection. RetroSynth integrates real-time intelligence across billions of building blocks to predict plausible, bench-ready synthetic pathways. By coupling automated retrosynthetic analysis with molecular design, RetroSynth enables high-throughput evaluation of large chemical spaces, helping ensure computationally prioritized molecules can be efficiently synthesized in the laboratory. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding the potential advantages of Schrödinger's computational platform, including the capabilities and potential advantages of Bunsen, its AI co-scientist, expectations relating to the use of Bunsen by BMS at scale, the potential development of novel functionality within Bunsen, and the successful deployment of Bunsen within BMS's research organization. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger's control, including its ability to further develop its computational platform, its reliance on third-party providers of cloud-based infrastructures to host its software solutions, and the ability to retain and hire key personnel on its business and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow BioPharma Dive on LinkedIn, or visit its blog, Extrapolations.com. Media gallery